Perceptic Raises $12M to Connect Drug Development

The big picture: London-based Perceptic has emerged from stealth with a $12M seed round led by Accel to build a single AI platform that follows a drug from early discovery through clinical development, a workflow currently handled by disconnected systems across most pharma companies. The company, founded by former Palantir engineers, already has paid production deployments running across multiple top-tier pharma companies, including CSL. Perceptic aims to consolidate the fragmented systems that plague drug development.

Why it matters:

• Costly & Time-Consuming: Drug development currently takes over a decade and costs upwards of $2 billion, a process Perceptic aims to streamline.
• Fragmented Workflows: Existing drug development relies on disconnected systems, leading to lost research insights, siloed clinical data, and manual decision-making.
• Growing Market: The global AI in drug discovery market, valued at $1.72B in 2024, is projected to surpass $8.5B by 2030, indicating strong demand for integrated solutions.

How it works:

• Integrated Lifecycle Platform: Perceptic builds a shared intelligence layer that connects the entire drug development lifecycle, from asset scouting and scientific evaluation to clinical data analysis, into a single operational system.
• AI Agent Harmonization: The platform employs AI agents tuned to various data types, including public knowledge, internal proprietary research, and external datasets, to harmonize information into one decision-making surface.
• Accelerated Outcomes: Customers use the platform to compress scientific due diligence from weeks to hours, scale asset screening from hundreds to thousands of compounds per minute, and achieve a 50-fold increase in clinical data extractions.

The catch: While Perceptic aims to provide a unified operating system for drug development, the challenge lies in whether large pharmaceutical companies will consolidate their existing point solutions onto a single platform. The industry’s traditional departmental structure, built around stages rather than the drug itself, may resist the platform logic Perceptic is betting on, despite the clear benefits of a connected intelligence layer.